The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.

Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, Monson JP

Clinical endocrinology1 Feb 1998Cited by 74 (Europe PMC)

PMID9579226DOI10.1046/j.1365-2265.1998.3641180.xPepBankPUB-09579226

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanNon-randomized trialMechanism
In hypopituitary adults at HC 10/10 mg, GH left total urinary cortisol metabolites unchanged: 9.67 (7.86-12.59) versus 9.93 (8.31-14.08) mg/24 hours.
In plain wordsIn hypopituitary adults at the lowest hydrocortisone schedule, GH did not change total urinary cortisol metabolites from before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeTotal urinary cortisol metabolites at HC 10/10 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Measurements
Total urinary cortisol metabolites
9.67 mg/24 hours
before GH, HC 10/10 mg, median (range 7.86-12.59)
Total urinary cortisol metabolites
9.93 mg/24 hours
after GH, HC 10/10 mg, median (range 8.31-14.08)
Source sentences
Summary
Total urinary CoM increased with rising doses of HC, but at each particular HC dose, were unchanged after GH (before versus after GH, median (range): 9.67 (7.86-12.59) versus 9.93 (8.31-14.08); 15.87 (12.37-31.39) versus 17.07 (12.64-23.81); 26.68 (19.07-42.14) versus 26.77 (8.01-37.62) mg/24 hours).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922601
02HumanNon-randomized trialMechanism
In hypopituitary adults at HC 20/10 mg, GH left total urinary cortisol metabolites unchanged: 15.87 (12.37-31.39) versus 17.07 (12.64-23.81) mg/24 hours.
In plain wordsIn hypopituitary adults at the middle hydrocortisone schedule, GH did not change total urinary cortisol metabolites from before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeTotal urinary cortisol metabolites at HC 20/10 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Measurements
Total urinary cortisol metabolites
15.87 mg/24 hours
before GH, HC 20/10 mg, median (range 12.37-31.39)
Total urinary cortisol metabolites
17.07 mg/24 hours
after GH, HC 20/10 mg, median (range 12.64-23.81)
Source sentences
Summary
Total urinary CoM increased with rising doses of HC, but at each particular HC dose, were unchanged after GH (before versus after GH, median (range): 9.67 (7.86-12.59) versus 9.93 (8.31-14.08); 15.87 (12.37-31.39) versus 17.07 (12.64-23.81); 26.68 (19.07-42.14) versus 26.77 (8.01-37.62) mg/24 hours).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922602
03HumanNon-randomized trialMechanism
In hypopituitary adults at HC 40/20 mg, GH left total urinary cortisol metabolites unchanged: 26.68 (19.07-42.14) versus 26.77 (8.01-37.62) mg/24 hours.
In plain wordsIn hypopituitary adults at the highest hydrocortisone schedule, GH did not change total urinary cortisol metabolites from before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeTotal urinary cortisol metabolites at HC 40/20 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Measurements
Total urinary cortisol metabolites
26.68 mg/24 hours
before GH, HC 40/20 mg, median (range 19.07-42.14)
Total urinary cortisol metabolites
26.77 mg/24 hours
after GH, HC 40/20 mg, median (range 8.01-37.62)
Source sentences
Summary
Total urinary CoM increased with rising doses of HC, but at each particular HC dose, were unchanged after GH (before versus after GH, median (range): 9.67 (7.86-12.59) versus 9.93 (8.31-14.08); 15.87 (12.37-31.39) versus 17.07 (12.64-23.81); 26.68 (19.07-42.14) versus 26.77 (8.01-37.62) mg/24 hours).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922603
04HumanNon-randomized trialMechanism
In hypopituitary adults at HC 10/10 mg, GH reduced the urine 11-hydroxy/11-oxo-CoM ratio from 1.22 (1.02-1.96) to 0.92 (0.83-1.63), P = 0.018.
In plain wordsIn hypopituitary adults at the lowest hydrocortisone schedule, GH reduced the urine cortisol metabolite ratio from before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseUrine 11-hydroxy/11-oxo-CoM at HC 10/10 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Measurements
Urine 11-hydroxy/11-oxo-CoM ratio
1.22 ratio
before GH, HC 10/10 mg, median (range 1.02-1.96)
Urine 11-hydroxy/11-oxo-CoM ratio
0.92 ratio
after GH, HC 10/10 mg, median (range 0.83-1.63)
Source sentences
Summary
The urine ratio 11-hydroxy/11-oxo-CoM decreased significantly with GH treatment, at each HC dose schedule (1.22 (1.02-1.96) versus 0.92 (0.83-1.63) P = 0.018; 1.53 (1.30-2.23) versus 1.23 (0.93-1.46) P = 0.018; 1.87 (1.45-2.70) versus 1.56 (1.22-1.79) P = 0.018).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922604
05HumanNon-randomized trialMechanism
In hypopituitary adults at HC 20/10 mg, GH reduced the urine 11-hydroxy/11-oxo-CoM ratio from 1.53 (1.30-2.23) to 1.23 (0.93-1.46), P = 0.018.
In plain wordsIn hypopituitary adults at the middle hydrocortisone schedule, GH reduced the urine cortisol metabolite ratio from before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseUrine 11-hydroxy/11-oxo-CoM at HC 20/10 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Measurements
Urine 11-hydroxy/11-oxo-CoM ratio
1.53 ratio
before GH, HC 20/10 mg, median (range 1.30-2.23)
Urine 11-hydroxy/11-oxo-CoM ratio
1.23 ratio
after GH, HC 20/10 mg, median (range 0.93-1.46)
Source sentences
Summary
The urine ratio 11-hydroxy/11-oxo-CoM decreased significantly with GH treatment, at each HC dose schedule (1.22 (1.02-1.96) versus 0.92 (0.83-1.63) P = 0.018; 1.53 (1.30-2.23) versus 1.23 (0.93-1.46) P = 0.018; 1.87 (1.45-2.70) versus 1.56 (1.22-1.79) P = 0.018).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922605
06HumanNon-randomized trialMechanism
In hypopituitary adults at HC 40/20 mg, GH reduced the urine 11-hydroxy/11-oxo-CoM ratio from 1.87 (1.45-2.70) to 1.56 (1.22-1.79), P = 0.018.
In plain wordsIn hypopituitary adults at the highest hydrocortisone schedule, GH reduced the urine cortisol metabolite ratio from before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseUrine 11-hydroxy/11-oxo-CoM at HC 40/20 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Measurements
Urine 11-hydroxy/11-oxo-CoM ratio
1.87 ratio
before GH, HC 40/20 mg, median (range 1.45-2.70)
Urine 11-hydroxy/11-oxo-CoM ratio
1.56 ratio
after GH, HC 40/20 mg, median (range 1.22-1.79)
Source sentences
Summary
The urine ratio 11-hydroxy/11-oxo-CoM decreased significantly with GH treatment, at each HC dose schedule (1.22 (1.02-1.96) versus 0.92 (0.83-1.63) P = 0.018; 1.53 (1.30-2.23) versus 1.23 (0.93-1.46) P = 0.018; 1.87 (1.45-2.70) versus 1.56 (1.22-1.79) P = 0.018).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922606
07HumanNon-randomized trialMechanism
In hypopituitary adults at HC 10/10 mg, GH reduced urinary tetrahydrocortisols/tetrahydrocortisone (P = 0.049).
In plain wordsIn hypopituitary adults at the lowest hydrocortisone schedule, GH reduced urinary tetrahydrocortisols relative to tetrahydrocortisone from before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseUrinary tetrahydrocortisols/tetrahydrocortisone at HC 10/10 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
The urinary ratio tetrahydrocortisols/tetrahydrocortisone, an alternative index of 11 beta-HSD activity, also fell with GH therapy at each HC dose (P = 0.049; P = 0.018; P = 0.043).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922607
08HumanNon-randomized trialMechanism
In hypopituitary adults at HC 20/10 mg, GH reduced urinary tetrahydrocortisols/tetrahydrocortisone (P = 0.018).
In plain wordsIn hypopituitary adults at the middle hydrocortisone schedule, GH reduced urinary tetrahydrocortisols relative to tetrahydrocortisone from before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseUrinary tetrahydrocortisols/tetrahydrocortisone at HC 20/10 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
The urinary ratio tetrahydrocortisols/tetrahydrocortisone, an alternative index of 11 beta-HSD activity, also fell with GH therapy at each HC dose (P = 0.049; P = 0.018; P = 0.043).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922608
09HumanNon-randomized trialMechanism
In hypopituitary adults at HC 40/20 mg, GH reduced urinary tetrahydrocortisols/tetrahydrocortisone (P = 0.043).
In plain wordsIn hypopituitary adults at the highest hydrocortisone schedule, GH reduced urinary tetrahydrocortisols relative to tetrahydrocortisone from before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseUrinary tetrahydrocortisols/tetrahydrocortisone at HC 40/20 mg
Study
n = 7
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
The urinary ratio tetrahydrocortisols/tetrahydrocortisone, an alternative index of 11 beta-HSD activity, also fell with GH therapy at each HC dose (P = 0.049; P = 0.018; P = 0.043).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922609
10HumanNon-randomized trialMechanism
In GH-deficient adults with intact ACTH reserve, GH produced urine steroid profile changes similar to those in hydrocortisone recipients.
In plain wordsIn GH-deficient adults with intact ACTH reserve, urine steroid changes during GH resembled those in patients receiving hydrocortisone.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedUrine steroid profiles with intact ACTH reserve
Study
n = 3
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
The patients with GH deficiency, but intact ACTH reserve, demonstrated changes in urine steroid profiles similar to the group receiving hydrocortisone replacement.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922611
11HumanNon-randomized trialMechanism
In hypopituitary adults, GH slightly increased the urinary 20-hydroxy/20-oxo-CoM ratio from before treatment.
In plain wordsIn hypopituitary adults, GH slightly increased a urinary cortisol metabolite ratio from before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary 20-hydroxy/20-oxo-CoM ratio
Study
n: not reported in source
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
In contrast, the urinary 20-hydroxy/20-oxo-CoM ratio exhibited a small increase with GH, suggesting that the changes observed above were not simply due to changes in redox status.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922610
12HumanNon-randomized trialMechanism
In hypopituitary adults, GH did not change urinary free cortisone from before treatment.
In plain wordsIn hypopituitary adults, GH did not change urinary free cortisone from before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeUrinary free cortisone
Study
n: not reported in source
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
Urinary free cortisone and urinary free cortisol/free cortisone ratios did not change with GH therapy, but the serum cortisol/ cortisone ratio fell significantly with GH therapy at each hydrocortisone dose.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922612
13HumanNon-randomized trialMechanism
In hypopituitary adults, GH did not change the urinary free cortisol/free cortisone ratio from before treatment.
In plain wordsIn hypopituitary adults, GH did not change the urine cortisol-to-cortisone ratio from before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeUrinary free cortisol/free cortisone ratio
Study
n: not reported in source
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
Urinary free cortisone and urinary free cortisol/free cortisone ratios did not change with GH therapy, but the serum cortisol/ cortisone ratio fell significantly with GH therapy at each hydrocortisone dose.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922613
14HumanNon-randomized trialMechanism
In hypopituitary adults, GH significantly reduced the serum cortisol/cortisone ratio at each hydrocortisone dose compared with before GH.
In plain wordsIn hypopituitary adults, GH reduced the blood cortisol-to-cortisone ratio at each hydrocortisone dose compared with before GH.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum cortisol/cortisone ratio
Study
n: not reported in source
Comparator
Before GH replacement
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
0.25 U/kg/week · 2 monthsAs given in this study (human).
Source sentences
Summary
Urinary free cortisone and urinary free cortisol/free cortisone ratios did not change with GH therapy, but the serum cortisol/ cortisone ratio fell significantly with GH therapy at each hydrocortisone dose.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients received increasing twice daily doses of hydrocortisone (HC) (10/10, 20/10, 40/20 mg) each week, before and during 2 months of GH replacement (0.25 U/kg/week).
Summary · context
Seven hypopituitary adults (three men and four women, age range 47-64 years) with combined GH and ACTH deficiency.
Summary · context
Three additional patients with GH deficiency, but intact ACTH reserve, were also studied.
Report a problemFND-0957922614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.